Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Siga Technologies has entered into a $3.2 million, one year contract with the US Army Medical Research and Material Command for the rapid identification and treatment of anti-viral diseases.
Subscribe to our email newsletter
Siga’s efforts will specifically aid the US Air Force Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat agents smallpox and adenovirus.
The company’s computational approach to the development of countermeasures is designed to interface with US Air Force programs for the identification of potential agents of bioterrorism, and will provide a key building block in the foundation of a rapid response capability to biological threat agents.
War-fighters and special operations forces may be called upon to operate in environments containing known or unknown pathogens. Until these pathogens can be accurately identified and neutralized, such forces remain vulnerable to the release of both natural and engineered viral pathogens.
“I am very excited about our relations with the USAF and Siga’s ability to participate in an effort which, I believe, is of crucial importance to our nation,” said Siga’s CEO, Dr Bernard Kasten. “I see a clear opportunity to continue working with the USAF in the future and to further advance SIGA’s antiviral counter measure programs.”